MaxCyte Announces Change in Substantial Shareholding
Why we think this is neutral
This RNS announcement does not contain any of the mandatory news types that would require a more detailed analysis. It simply reports a change in substantial shareholding by BlackRock, Inc. Without any financial or operational updates, the sentiment is neutral.
Key Points
- BlackRock, Inc. now holds 10.14% of MaxCyte's voting rights
Summary
The healthcare company reports a change in substantial shareholding by BlackRock, Inc.
MaxCyte, Inc., a medical devices company, has announced a change in substantial shareholding. BlackRock, Inc. now holds 10.14% of the company's voting rights, up from 9.98% previously.
DIRECTOR DEALINGS